Indemnification agreements with each director and executive officer
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Alexandria Forbes
Also a director
President and Chief Executive Officer and Director
|
61 |
Since 2015
11 years
|
Not stated | $8,330,006 | |
|
Richard Giroux
Chief Operating Officer and Chief Financial Officer
|
53 | Not stated | Not stated | $8,148,500 | |
|
Robert K. Zeldin
Chief Medical Officer
|
63 | Not stated | Not stated | $1,616,123 | |
|
Robert J. Wollin
General Counsel and Secretary
|
50 | Not stated | 2019 | Not reported | |
|
Penny Renee Fleck
CHIEF DEVELOPMENT OFFICER
Title from the Form 4 dated May 13, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Stuart Naylor
CHIEF SCI OFCR, OPHTHALMOLOGY
Title from the Form 4 dated Oct 6, 2026
|
63 | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Sep 23, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Keith R. Harris, Ph.D.
Board chair
|
73 |
2015
11 years
|
Independent | None stated | Global Connectivity PLC | $674,250 | |
|
Alexandria Forbes, Ph.D.
CEO
|
61 |
2015
11 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Ellen Hukkelhoven, Ph.D.
|
39 |
2017
9 years
|
Not independent | None stated | Freenome Holdings, Inc., Partner Therapeutics, Inc. | $296,550 | |
|
Nicole Seligman
|
69 |
2019
7 years
|
Independent | None stated | Intuitive Machines, Inc., OpenAI, Praetorian Acquisition Corp. | $406,050 | |
|
Debra Yu, M.D.
|
61 |
2022
4 years
|
Independent | None stated | JW (Cayman) Therapeutics Co. Ltd. | $389,050 | |
|
Thomas E. Shenk, Ph.D.
|
79 |
2015
11 years
|
Independent | None stated | None stated | $398,550 | |
|
Lord Mendoza
|
66 |
2015
11 years
|
Independent | None stated | None stated | $396,550 | |
|
Alan M. Sebulsky
Joined Sep 23, 2026
|
- | - | - |
Science and Technology Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Indemnification agreements with each director and executive officer
Senior secured financing (Notes Purchase Agreement) with initial $75.0 million notes issuance
Company repurchased 2,300,000 ordinary shares under a share purchase agreement
Purchased 7,500,000 ordinary shares in August 2024 public offering
Purchased 1,250,000 ordinary shares in August 2024 public offering
Purchased 375,000 ordinary shares in August 2024 public offering
Purchased 1,600,000 ordinary shares in April 2026 public offering
Purchased 555,555 ordinary shares in April 2026 public offering
Purchased 400,000 ordinary shares in April 2026 public offering
Strategic collaboration with upfront cash payment to the Company and related framework agreements
Nominal equity interest in Hologen held by Dr. Forbes and Mr. Giroux, who serve on Hologen advisory boards
Asset Purchase Agreement for RPGR gene therapy product and related assets with upfront cash purchase price to Seller
Loading...